Related references
Note: Only part of the references are listed.Analysis of Nonhuman N-Glycans as the Minor Constituents in Recombinant Monoclonal Antibody Pharmaceuticals
Eiki Maeda et al.
ANALYTICAL CHEMISTRY (2012)
Introducing Site-Specific Glycosylation Using Protein Engineering Techniques Reduces the Immunogenicity of β-Lactoglobulin
Yoshiyuki Tatsumi et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2012)
Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach
Alex Eon-Duval et al.
BIOTECHNOLOGY PROGRESS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Immunogenicity of protein aggregates-Concerns and realities
Wei Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals
Angelina Bozhinov et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing
Theo Rispens et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Classification of protein aggregates
Linda O. Narhi et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice
Dipak S. Pisal et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release
Wim Jiskoot et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene
Miranda M. C. Van Beers et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Particles in therapeutic protein formulations, Part 1: Overview of analytical methods
Sarah Zoells et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Glycoproteins are species-specific markers and major IgE reactants in grass pollens
Helene Manduzio et al.
PLANT BIOTECHNOLOGY JOURNAL (2012)
Chemical Modifications in Aggregates of Recombinant Human Insulin Induced by Metal-Catalyzed Oxidation: Covalent Cross-Linking via Michael Addition to Tyrosine Oxidation Products
Riccardo Torosantucci et al.
PHARMACEUTICAL RESEARCH (2012)
Biologics Formulation Factors Affecting Metal Leachables from Stainless Steel
Shuxia Zhou et al.
AAPS PHARMSCITECH (2011)
Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope
Bas de Laat et al.
ARTHRITIS AND RHEUMATISM (2011)
Taking immunogenicity assessment of therapeutic proteins to the next level
I. C. Buettel et al.
BIOLOGICALS (2011)
Prediction of the aggregation propensity of proteins from the primary sequence: Aggregation properties of proteomes
Virginia Castillo et al.
BIOTECHNOLOGY JOURNAL (2011)
T cell-independent B cell memory
Thierry Defrance et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions
Quanzhou Luo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
n-Dodecyl-β-d-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity
Robert A. Rifkin et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2011)
Glass Particles as an Adjuvant: A Model for Adverse Immunogenicity of Therapeutic Proteins
Amber Haynes Fradkin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Satish Kumar Singh
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development
John den Engelsman et al.
PHARMACEUTICAL RESEARCH (2011)
Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions
Sandeep Kumar et al.
PHARMACEUTICAL RESEARCH (2011)
Immunogenicity of Therapeutic Proteins: The Use of Animal Models
Vera Brinks et al.
PHARMACEUTICAL RESEARCH (2011)
Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
Miranda M. C. van Beers et al.
PHARMACEUTICAL RESEARCH (2011)
Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk
Vered Padler-Karavani et al.
XENOTRANSPLANTATION (2011)
Aggregation of a Monoclonal Antibody Induced by Adsorption to Stainless Steel
Jared S. Bee et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis
Miranda M. C. van Beers et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2010)
An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics
Satish K. Singh et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins
Carlos J. Bosques et al.
NATURE BIOTECHNOLOGY (2010)
Biopharmaceutical benchmarks 2010
Gary Walsh
NATURE BIOTECHNOLOGY (2010)
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Darius Ghaderi et al.
NATURE BIOTECHNOLOGY (2010)
Aggregated Recombinant Human Interferon Beta Induces Antibodies but No Memory in Immune-Tolerant Transgenic Mice
Miranda M. C. van Beers et al.
PHARMACEUTICAL RESEARCH (2010)
Stability of Protein Pharmaceuticals: An Update
Mark Cornell Manning et al.
PHARMACEUTICAL RESEARCH (2010)
Immunological mechanism underlying the immune response to recombinant human protein therapeutics
Melody Sauerborn et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
A Clone Screening Method Using mRNA Levels to Determine Specific Productivity and Product Quality for Monoclonal Antibodies
Christina J. Lee et al.
BIOTECHNOLOGY AND BIOENGINEERING (2009)
Application of High Hydrostatic Pressure to Dissociate Aggregates and Refold Proteins
Matthew B. Seefeldt et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2009)
Immunogenicity of Aggregates of Recombinant Human Growth Hormone in Mouse Models
Amber Haynes Fradkin et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality
John F. Carpenter et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Human immunoglobulin allotypes Possible implications for immunogenicity
Roy Jefferis et al.
MABS (2009)
Quality by design for biopharmaceuticals
Anurag S. Rathore et al.
NATURE BIOTECHNOLOGY (2009)
MARKET WATCH Sales of biologics to show robust growth through to 2013
Michael Goodman
NATURE REVIEWS DRUG DISCOVERY (2009)
A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme-A Preclinical and Phase I Investigation
David Aviezer et al.
PLOS ONE (2009)
Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
Royston Jefferis
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Biosimilar therapeutics-what do we need to consider?
Huub d Schellekens
CLINICAL KIDNEY JOURNAL (2009)
Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose
Christine H. Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy
Christine H. Chung
ONCOLOGIST (2008)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
Jun Qian et al.
ANALYTICAL BIOCHEMISTRY (2007)
A role for protein misfolding in immunogenicity of biopharmaceuticals
Coen Maas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: Biochemical and immunological studies
Zafar Rasheed et al.
LIFE SCIENCES (2006)
Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity
Hester A. Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Post-translational modifications in the context of therapeutic proteins
Gary Walsh et al.
NATURE BIOTECHNOLOGY (2006)
Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation
Amartya Basu et al.
BIOCONJUGATE CHEMISTRY (2006)
Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation
S Hermeling et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Effects of protein aggregates: An immunologic perspective
Amy S. Rosenberg
AAPS JOURNAL (2006)
Protein aggregation and bioprocessing
Mary E. M. Cromwell et al.
AAPS JOURNAL (2006)
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model
DP Baker et al.
BIOCONJUGATE CHEMISTRY (2006)
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2005)
The α-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy
U Galili
IMMUNOLOGY AND CELL BIOLOGY (2005)
Carbohydrates in xenotransplantation
M Ezzelarab et al.
IMMUNOLOGY AND CELL BIOLOGY (2005)
Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells
M Bardor et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins
AM Fernandez-Escamilla et al.
NATURE BIOTECHNOLOGY (2004)
Structure-immunogenicity relationships of therapeutic proteins
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2004)
Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures
M Bardor et al.
PLANT BIOTECHNOLOGY JOURNAL (2003)
Immunoreactivity in mammals of two typical plant glyco-epitopes, core α(1,3)-fucose and core xylose
M Bardor et al.
GLYCOBIOLOGY (2003)
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles
B Chackerian et al.
JOURNAL OF IMMUNOLOGY (2002)
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
H Schellekens
CLINICAL THERAPEUTICS (2002)
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses
A Jegerlehner et al.
VACCINE (2002)
Bioequivalence and the immunogenicity of biopharmaceuticals
H Schellekens
NATURE REVIEWS DRUG DISCOVERY (2002)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
